IC
IMVT icon

Ikarian Capital’s Immunovant IMVT Stock Holding History

Ikarian Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-400,000
Closed -$6.84M – 163
2025
Q1 		$6.84M Buy
+400,000
New +$8.37M 0.84% 25
2024
Q1 		– Sell
-164,700
Closed -$6.94M – 161
2023
Q4 		$6.94M Buy
164,700
+159,166
+2,876% +$5.86M 0.65% 53
2023
Q3 		$21.2M Sell
5,534
-70,466
-93% -$1.59M 2.56% 10
2023
Q2 		$1.44M Buy
+76,000
New +$1.42M 0.23% 77
2021
Q3 		– Sell
-57,700
Closed -$610K – 239
2021
Q2 		$610K Sell
57,700
-185,100
-76% -$2.58M 0.05% 178
2021
Q1 		$3.9M Buy
+242,800
New +$6.4M 0.13% 146

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Ikarian Capital's IMVT Position: Q1 2025 in Review

Ikarian Capital sold out of Immunovant (IMVT) in Q1 2025, closing a stake of 600 shares — an estimated $12.6K sold.

Ikarian Capital first reported a position in IMVT in Q4 2019 and held it in 15 quarters. The position peaked at $17.2M in Q4 2022. 193 funds tracked by Wall St. Rank hold IMVT as of Q1 2025.

  • Ikarian Capital reported no remaining Immunovant position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 600 Immunovant shares in Q1 2025, an estimated $12.6K.
  • Ikarian Capital first reported a position in Immunovant in Q4 2019 and held it in 15 quarters.
  • Ikarian Capital's Immunovant position peaked at $17.2M in Q4 2022.
  • 193 funds tracked by Wall St. Rank held Immunovant as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.